SCHEMBL12513331

SCHEMBL12513331

C=C(C)OC(=O)[C@@H](N)Cc1ccc(NC(=O)OC(C)(C)C)nc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.44
NAMPT P43490 2/20 0.42
GRIN2B Q13224 1/20 0.38
CYP17A1 P05093 1/20 0.36
MAPKAPK2 P49137 4/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
SCN9A Q15858 1/20 0.34
AURKA O14965 1/20 0.34
RPS6KB1 P23443 1/20 0.34
ATR Q13535 1/20 0.34
SLC7A5 Q01650 1/20 0.34
RET P07949 1/20 0.34
BCL2 P10415 1/20 0.34
MKNK2 Q9HBH9 1/20 0.33
LTA4H P09960 1/20 0.33
SCD O00767 1/20 0.32
IGF1R P08069 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3211479 0.90 HDAC1 (0.47) HDAC1NAMPTGRIN2BCYP17A1MAPKAPK2
SCHEMBL1429937 0.90 HDAC1 (0.47) HDAC1NAMPTGRIN2BCYP17A1MAPKAPK2
SCHEMBL2217180 0.85 SLC7A5 (0.47) HDAC1NAMPTGRIN2BCYP17A1SLC7A5
SCHEMBL2217184 0.85 SLC7A5 (0.47) HDAC1NAMPTGRIN2BCYP17A1SLC7A5
SCHEMBL13577799 0.82 HDAC1 (0.45) HDAC1NAMPTGRIN2BCYP17A1MAPKAPK2
SCHEMBL7257280 0.79 NAMPT (0.46) HDAC1NAMPTGRIN2BCYP17A1MAPKAPK2
SCHEMBL5076532 0.79 NAMPT (0.47) HDAC1NAMPTGRIN2BCYP17A1MAPKAPK2
SCHEMBL7260124 0.77 NAMPT (0.44) HDAC1NAMPTGRIN2BCYP17A1GSK3B
SCHEMBL6058751 0.77 NAMPT (0.44) HDAC1NAMPTGRIN2BCYP17A1GSK3B
SCHEMBL10087556 0.77 NAMPT (0.49) HDAC1NAMPTGRIN2BCYP17A1MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178130-A1 MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa SANOFI-AVENTIS (FR) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178130-A1 MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa TFPI, TFPI2, SERPINC1 HDAC1 208/4885NAMPT 1007/4885GRIN2B 4680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.